Back to Trials
NCT07525947PHASE1RecruitingAccepts Healthy Volunteers

A Single Dose, Phase 1 Study of JADE101 in Healthy Japanese and Chinese Participants

Jade Biosciences, Inc.

Start Date

5/1/2026

Completion Date

5/1/2027

Summary

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of JADE101 in healthy Japanese and Chinese participants.

Eligibility Criteria

Age Range: 18 years to 55 years

Inclusion Criteria: 1. Healthy male or female participants 18-55 years of age, inclusive 2. First-generation Japanese or Chinese participants born in Japan/China 3. A body weight between 40-100 kg and a body mass index (BMI) between 18.0 - 32.0 kg/m2 (all inclusive) at screening 4. Willing and able to comply with the study site stay, scheduled visits, and study procedures 5. Willing and able to comply with contraceptive and lifestyle requirements from admission through the end of the study Exclusion Criteria: 1. Harmful alcohol use 2. Smoking/vaping or heavy tobacco use within 2 years prior to screening 3. Known history of abuse of illicit drugs 4. Nursing, lactating or pregnant, or who have plans to become pregnant during the study 5. Known history of clinically significant disease 6. Known history of immunodeficiency disorder 7. History of clinically significant allergic reactions or hypersensitivity

Interventions

DRUG

JADE101

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Healthy Volunteers (HV)

Locations

Parexel Early Phase Clinical Unit (EPCU)

Glendale, California 91206

United States